Therapy Areas: Diabetes
Circularity announces new clinical trial of FDA-approved drug and IDE device D'OXYVA in COVID-19 patients
22 April 2020 -

Biotech company Circularity Healthcare LLC reported on Tuesday the launch of a new clinical trial of US FDA-approved drug and IDE device D'OXYVA that could increase the rate of recovery of COVID-19 patients with at-risk underlying health conditions.

The company said the IDE device D'OXYVA (deoxyhemoglobin vasodilator) is a non-toxic, non-invasive microcirculation transdermal device that improves overall oxygen-rich blood flow. The device has been shown to heal diabetic wounds, reduce the risks of amputations, prevent sepsis and septic shock, improve blood pressure as well as general vital organ function of the pancreas, liver, brain and kidneys.

Additionally, the clinical trials are now waiting IRB approvals and are about to launch under existing company contracts at multiple sites including Harvard, Yale, M.I.T, USC and UCLA, with more physicians and patients being invited to participate. Since the product can be monitored at home, potential patients do not have to be currently admitted to a hospital in order to take part in the trial.

Login
Username:

Password: